Linsitinib manufacturers and suppliers

Linsitinib suppliers

Linsitinib

CAS:: 867160-71-2

MF:: C26H23N5O

MW:: 421.49

Suppliers by country/region

Company Type

Properties

Melting point:: >175°C (dec.)

Density: 1.39

storage temp.: -20°C

solubility: Soluble in DMSO (up to 30 mg/ml)

form: solid

pka: 14.84±0.40(Predicted)

color: Yellow

Stability:: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Use

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model.

You can find Linsitinib suppliers, manufacturers, and distributors from countries such as China, United States and the Canada here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.